Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • About
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Non-radiographic Evidence-AxSpA”

4 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 4 of 4 results

Not applicableUnknownNCT05427942
What this trial is testing

Yuflyma® (Adalimumab), Patient Experience After Switching

Who this might be right for
Rheumatoid ArthritisAnkylosing SpondylarthritisAxial Spondyloarthritis Without Radiographic Evidence of Ankylosing Spondylitis+3 more
Celltrion HealthCare France 300
Early research (Phase 1)Study completedNCT02019602
What this trial is testing

A Multicener, Postmarketing Study Evaluating the Transfer of Cimzia From the Mother to the Infant Via the Placenta

Who this might be right for
Axial Spondyloarthritis (AxSpA)Non-radiographic Evidence-AxSpAAnkylosing Spondylitis+3 more
UCB BIOSCIENCES, Inc. 37
Large-scale testing (Phase 3)Study completedNCT02552212
What this trial is testing

Multicenter Study Evaluating Certolizumab Pegol Compared to Placebo in Subjects With axSpA Without X-ray Evidence of AS

Who this might be right for
Axial SpondyloarthritisNonradiographic Axial SpondyloarthritisNr-axSpA
UCB BIOSCIENCES GmbH 317
Early research (Phase 1)Study completedNCT02154425
What this trial is testing

A Multicenter, Postmarketing Study Evaluating the Concentration of Cimzia® in Mature Breast Milk of Lactating Mothers

Who this might be right for
Axial Spondyloarthritis (AxSpA)Non-radiographic Evidence-AxSpAAnkylosing Spondylitis+3 more
UCB BIOSCIENCES, Inc. 17